Damora Therapeutics (DMRA)
Market Price (8/21/2026): $30.32 | Market Cap: $1.9 BilSector: Health Care | Industry: Biotechnology
Damora Therapeutics (DMRA)
Market Price (8/21/2026): $30.32Market Cap: $1.9 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.71 | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -271 Mil Stock price has recently run up significantly12M Rtn12 month market price return is 797% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% High stock price volatilityVol 12M is 474% Key risksDMRA key risks include [1] potential clinical trial or regulatory failure of its key product candidates, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -29% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.71 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -271 Mil |
| Stock price has recently run up significantly12M Rtn12 month market price return is 797% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% |
| High stock price volatilityVol 12M is 474% |
| Key risksDMRA key risks include [1] potential clinical trial or regulatory failure of its key product candidates, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/20/2026
Damora Therapeutics (DMRA) stock has gained about 20% since 4/30/2026 because of the following key factors:
1. Initiation of Phase 1/1b CLARITY-101 Clinical Trial for Lead Candidate DMR-001. Damora Therapeutics commenced the global Phase 1/1b CLARITY-101 clinical trial for DMR-001 on August 5, 2026, following health authority approvals. DMR-001 is an investigational antibody targeting mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). This advancement into clinical trials marked a significant milestone, highlighting the company's progress in developing a potential first mutCALR-targeted therapy for an underserved patient population.
2. Promising Preclinical Data for DMR-001 Presented at EHA 2026 Congress. In June 2026, Damora Therapeutics presented preclinical data for DMR-001 at the European Hematology Association (EHA) 2026 Congress. These data demonstrated DMR-001's strong potential, showing up to 30-fold higher binding affinity and a five-fold longer half-life compared to a reference anti-mutCALR antibody. This supports a predicted convenient once-monthly subcutaneous dosing regimen for the drug.
Show more
Damora Therapeutics (DMRA) stock has gained about 20% since 4/30/2026 because of the following key factors:
1. Initiation of Phase 1/1b CLARITY-101 Clinical Trial for Lead Candidate DMR-001. Damora Therapeutics commenced the global Phase 1/1b CLARITY-101 clinical trial for DMR-001 on August 5, 2026, following health authority approvals. DMR-001 is an investigational antibody targeting mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). This advancement into clinical trials marked a significant milestone, highlighting the company's progress in developing a potential first mutCALR-targeted therapy for an underserved patient population.
2. Promising Preclinical Data for DMR-001 Presented at EHA 2026 Congress. In June 2026, Damora Therapeutics presented preclinical data for DMR-001 at the European Hematology Association (EHA) 2026 Congress. These data demonstrated DMR-001's strong potential, showing up to 30-fold higher binding affinity and a five-fold longer half-life compared to a reference anti-mutCALR antibody. This supports a predicted convenient once-monthly subcutaneous dosing regimen for the drug.
Show more
Updated on 8/20/2026
Damora Therapeutics (DMRA) stock has gained about 20% since 4/30/2026 because of the following key factors:
1. Initiation of Phase 1/1b CLARITY-101 Clinical Trial for Lead Candidate DMR-001. Damora Therapeutics commenced the global Phase 1/1b CLARITY-101 clinical trial for DMR-001 on August 5, 2026, following health authority approvals. DMR-001 is an investigational antibody targeting mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). This advancement into clinical trials marked a significant milestone, highlighting the company's progress in developing a potential first mutCALR-targeted therapy for an underserved patient population.
2. Promising Preclinical Data for DMR-001 Presented at EHA 2026 Congress. In June 2026, Damora Therapeutics presented preclinical data for DMR-001 at the European Hematology Association (EHA) 2026 Congress. These data demonstrated DMR-001's strong potential, showing up to 30-fold higher binding affinity and a five-fold longer half-life compared to a reference anti-mutCALR antibody. This supports a predicted convenient once-monthly subcutaneous dosing regimen for the drug.
3. Strong Cash Position Providing Extended Operational Runway. As of the end of fiscal Q2 2026 (June 30, 2026), Damora Therapeutics reported a robust cash and cash equivalents balance of $540.5 million. Management anticipates this financial position will be sufficient to fund operations into the second half of 2029, providing significant stability for its development programs.
4. Positive Analyst Coverage and Price Targets. Throughout July and August 2026, several Wall Street analysts reiterated "Buy" or "Outperform" ratings for Damora Therapeutics and maintained or increased their price targets. For example, Jefferies initiated coverage with a "Buy" rating and a $50.00 price target on July 27, 2026, while Wedbush increased its price objective from $35.00 to $40.00 on July 30, 2026. The company received an average 12-month price target of $44.67 from analysts.
5. Better-than-Expected Fiscal Q2 2026 Earnings. Damora Therapeutics announced its fiscal Q2 2026 financial results (for the quarter ended June 30, 2026) on August 10, 2026. The company reported an Earnings Per Share (EPS) of -$0.39, which surpassed the consensus analyst estimate of -$0.45 by $0.06. This earnings beat, despite a net loss of $31.2 million, provided a positive signal to investors.
Show less
Damora Therapeutics (DMRA) stock has gained about 20% since 4/30/2026 because of the following key factors:
1. Initiation of Phase 1/1b CLARITY-101 Clinical Trial for Lead Candidate DMR-001. Damora Therapeutics commenced the global Phase 1/1b CLARITY-101 clinical trial for DMR-001 on August 5, 2026, following health authority approvals. DMR-001 is an investigational antibody targeting mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). This advancement into clinical trials marked a significant milestone, highlighting the company's progress in developing a potential first mutCALR-targeted therapy for an underserved patient population.
2. Promising Preclinical Data for DMR-001 Presented at EHA 2026 Congress. In June 2026, Damora Therapeutics presented preclinical data for DMR-001 at the European Hematology Association (EHA) 2026 Congress. These data demonstrated DMR-001's strong potential, showing up to 30-fold higher binding affinity and a five-fold longer half-life compared to a reference anti-mutCALR antibody. This supports a predicted convenient once-monthly subcutaneous dosing regimen for the drug.
3. Strong Cash Position Providing Extended Operational Runway. As of the end of fiscal Q2 2026 (June 30, 2026), Damora Therapeutics reported a robust cash and cash equivalents balance of $540.5 million. Management anticipates this financial position will be sufficient to fund operations into the second half of 2029, providing significant stability for its development programs.
4. Positive Analyst Coverage and Price Targets. Throughout July and August 2026, several Wall Street analysts reiterated "Buy" or "Outperform" ratings for Damora Therapeutics and maintained or increased their price targets. For example, Jefferies initiated coverage with a "Buy" rating and a $50.00 price target on July 27, 2026, while Wedbush increased its price objective from $35.00 to $40.00 on July 30, 2026. The company received an average 12-month price target of $44.67 from analysts.
5. Better-than-Expected Fiscal Q2 2026 Earnings. Damora Therapeutics announced its fiscal Q2 2026 financial results (for the quarter ended June 30, 2026) on August 10, 2026. The company reported an Earnings Per Share (EPS) of -$0.39, which surpassed the consensus analyst estimate of -$0.45 by $0.06. This earnings beat, despite a net loss of $31.2 million, provided a positive signal to investors.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 18.1% change in DMRA stock from 4/30/2026 to 8/20/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 25.66 | 30.31 | 18.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 61 | -97.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2026 to 8/20/2026| Return | Correlation | |
|---|---|---|
| DMRA | 18.1% | |
| Market (SPY) | 6.1% | 12.4% |
| Sector (XLV) | 18.1% | 13.1% |
Fundamental Drivers
The 15.5% change in DMRA stock from 1/31/2026 to 8/20/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 26.23 | 30.31 | 15.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 61 | -97.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 8/20/2026| Return | Correlation | |
|---|---|---|
| DMRA | 15.5% | |
| Market (SPY) | 10.5% | 16.6% |
| Sector (XLV) | 11.9% | 18.4% |
Fundamental Drivers
The 821.3% change in DMRA stock from 7/31/2025 to 8/20/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.29 | 30.31 | 821.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 61 | -97.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 8/20/2026| Return | Correlation | |
|---|---|---|
| DMRA | 821.3% | |
| Market (SPY) | 21.7% | 5.4% |
| Sector (XLV) | 33.9% | 4.6% |
Fundamental Drivers
The -60.6% change in DMRA stock from 7/31/2023 to 8/20/2026 was primarily driven by a -98.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312023 | 8202026 | Change |
|---|---|---|---|
| Stock Price ($) | 77.00 | 30.31 | -60.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 61 | -98.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2023 to 8/20/2026| Return | Correlation | |
|---|---|---|
| DMRA | -60.6% | |
| Market (SPY) | 72.5% | 10.0% |
| Sector (XLV) | 34.5% | 7.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DMRA Return | -76% | -62% | -37% | -74% | 395% | 41% | -90% |
| Peers Return | -45% | 2% | -35% | -4% | 20% | 19% | -49% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| DMRA Win Rate | 17% | 33% | 58% | 33% | 58% | 62% | |
| Peers Win Rate | 33% | 50% | 46% | 50% | 48% | 72% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| DMRA Max Drawdown | -83% | -68% | -84% | -79% | -72% | -44% | |
| Peers Max Drawdown | -60% | -51% | -64% | -52% | -66% | -46% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: INCY, GERN, KPTI, PRLD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/20/2026 (YTD)
How Low Can It Go
| Event | DMRA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -53.8% | -18.8% |
| % Gain to Breakeven | 116.7% | 23.1% |
| Time to Breakeven | 180 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -34.4% | -6.7% |
| % Gain to Breakeven | 52.4% | 7.1% |
| Time to Breakeven | 20 days | 31 days |
In The Past
Damora Therapeutics's stock fell -53.8% during the 2025 US Tariff Shock. Such a loss loss requires a 116.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | DMRA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -53.8% | -18.8% |
| % Gain to Breakeven | 116.7% | 23.1% |
| Time to Breakeven | 180 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -34.4% | -6.7% |
| % Gain to Breakeven | 52.4% | 7.1% |
| Time to Breakeven | 20 days | 31 days |
In The Past
Damora Therapeutics's stock fell -53.8% during the 2025 US Tariff Shock. Such a loss loss requires a 116.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Damora Therapeutics (DMRA)
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
AI Analysis | Feedback
- An early-stage Vertex Pharmaceuticals focused on developing novel treatments for fibrosis and cancer.
- A clinical-stage Regeneron Pharmaceuticals focused on developing drugs for fibrosis and cancer.
AI Analysis | Feedback
Major products of Damora Therapeutics (DMRA):
- GB2064: A product candidate in Phase IIa for the treatment of myelofibrosis.
- GB0139: An inhaled galectin-3 inhibitor in Phase IIb for severe fibrotic lung diseases like idiopathic pulmonary fibrosis.
- GB1211: A selective oral galectin-3 inhibitor in Phase IIa for cancer and Phase Ib/IIa for fibrosis.
AI Analysis | Feedback
Damora Therapeutics (DMRA) is a clinical-stage biotechnology company focused on developing molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. Its product candidates, such as GB2064, GB0139, and GB1211, are currently in various phases of clinical trials (Phase IIa, Phase IIb, and Phase Ib/IIa).
As a clinical-stage biotechnology company with no commercialized products on the market, Damora Therapeutics does not currently have major customers, either individuals or other companies, who purchase its products or services.
AI Analysis | Feedback
- Lonza Ltd. (SIX: LONN)
- Callery Chemicals (Parent: MSA Safety Incorporated (NYSE: MSA))
- Hovione LLC
- Siegfried AG (SIX: SFZN)
AI Analysis | Feedback
Sherwin Sattarzadeh, Interim Principal Executive Officer & Chief Operating Officer
Sherwin Sattarzadeh was appointed Interim Principal Executive Officer in February 2026, after serving as Chief Operating Officer since January 2026. He brings over two decades of industry experience in drug development and company lifecycle. Prior to joining Galecto (now Damora Therapeutics), he served as Chief Business Officer at Blueprint Medicines Corporation from January 2025 to October 2025. During his 10 years at Blueprint Medicines, Mr. Sattarzadeh held various positions of increasing responsibility, including Head of Regulatory Affairs, Chief of Staff, and SVP Strategic Operations. He has a background in hematology/oncology and rare disease drug development, having contributed to the global approvals of therapies such as AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib).
Lori Firmani, Chief Financial Officer
Lori Firmani was appointed Chief Financial Officer in November 2025, having previously served as Interim Chief Financial Officer and Vice President, Finance and Corporate Controller. She possesses over 25 years of experience in financial roles within the biotech sector. Ms. Firmani served as Chief Financial Officer of Spring Bank Pharmaceuticals, Inc. from April 2020 until its acquisition in November 2020.
Becker Hewes, M.D., Chief Medical Officer
Dr. Becker Hewes was appointed Chief Medical Officer in January 2026. He brings over two decades of experience in drug development in public biotechnology companies. Most recently, he served as Chief Medical Officer at Blueprint Medicines, where he led the development of an industry-leading pipeline and the approval of AYVAKIT® (avapritinib) for indolent and advanced systemic mastocytosis. His previous experience in hematology/oncology drug development includes leading clinical development and translational medicine efforts for multiple early-stage oncology programs and registration programs for therapies like Kisqali® (ribociclib) and Bosulif® (bosutinib).
Garrett Winslow, General Counsel and Corporate Secretary
Garrett Winslow serves as General Counsel and Corporate Secretary, and also holds the title of Senior Vice President. He has more than 15 years of experience working with public companies in the life sciences industry.
Matthew Kronmiller, Executive Vice President of Strategy and Chief Business Officer
Matthew Kronmiller holds the position of Executive Vice President of Strategy and Chief Business Officer.
AI Analysis | Feedback
<h3>Key Risks to Damora Therapeutics (DMRA)</h3>
<ol>
<li><strong>Clinical Trial Failure and Regulatory Approval Risk:</strong> Damora Therapeutics, as a clinical-stage biotechnology company, faces significant risk from the potential failure of its product candidates in ongoing and future clinical trials. The success of GB2064 (Phase IIa for myelofibrosis), GB0139 (Phase IIb for severe fibrotic lung diseases), and GB1211 (Phase IIa for cancer, Phase Ib/IIa for fibrosis) is uncertain. Failure to demonstrate efficacy or safety, or encountering unforeseen side effects, could lead to delays, abandonment of programs, or an inability to obtain necessary regulatory approvals, severely impacting the company's prospects and future revenue streams. </li>
<li><strong>Significant Capital Requirements and Funding Risk:</strong> Developing multiple product candidates through various clinical phases is a capital-intensive endeavor. Damora Therapeutics requires substantial ongoing funding to complete its clinical trials, pursue regulatory approvals, and potentially commercialize its molecules. There is a risk that the company may not be able to secure additional financing on favorable terms, or at all, if and when needed. Insufficient funding could force the company to delay, scale back, or discontinue its critical product development programs.</li>
<li><strong>Competition and Market Acceptance Risk:</strong> The therapeutic areas Damora Therapeutics targets, such as fibrosis, cancer, and inflammation, are highly competitive and characterized by rapid technological change. Even if its product candidates receive regulatory approval, there is a risk that they may not achieve significant market acceptance due to competition from existing treatments, superior new therapies developed by competitors, or challenges related to pricing, reimbursement, and market access. </li>
</ol>AI Analysis | Feedback
null
AI Analysis | Feedback
Damora Therapeutics (NASDAQ: DMRA) focuses on developing therapeutics for mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs), which include essential thrombocythemia (ET) and myelofibrosis (MF).
The addressable market for Damora Therapeutics' main products, which target mutCALR-driven MPNs, is approximately 42,000 patients in the United States.
AI Analysis | Feedback
Damora Therapeutics (NASDAQ: DMRA), a clinical-stage biotechnology company, is currently focused on advancing its pipeline of drug candidates for cancer and fibrosis, with no product revenue reported for recent fiscal periods or forecast through 2029. Therefore, expected drivers of future revenue growth over the next 2-3 years are intrinsically tied to the successful progression of its clinical pipeline and strategic collaborations.
Here are 3-5 expected drivers of future revenue growth for Damora Therapeutics:
- Advancement of the DMR-001 Program: The successful progression of DMR-001, an antibody therapeutic for mutant-calreticulin essential thrombocythemia and myelofibrosis, is a key driver. The company anticipates submitting an Investigational New Drug (IND) or Clinical Trial Application (CTA) for DMR-001 in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027. Positive outcomes from these milestones would significantly de-risk the asset, making it more attractive for potential licensing deals or future commercialization.
- Progression of Additional Oncology Pipeline Candidates (DMR-002, DMR-003, GB3226): Damora Therapeutics plans to submit an IND or CTA for DMR-002 in the second half of 2026 and for DMR-003 in 2027. Additionally, the preclinical drug GB3226 for acute myeloid leukemia (AML) has an IND submission planned for Q1 2026. Successfully moving these candidates into clinical trials expands the company's pipeline and creates additional opportunities for future value creation, including potential partnership revenue.
- Positive Clinical Trial Results and Advancement of GB1211 and GB0139: The company's ongoing clinical programs for GB1211 (a galectin-3 inhibitor in Phase IIa for cancer and Phase Ib/IIa for fibrosis, and also indicated for liver disease) and GB0139 (an inhaled galectin-3 inhibitor in Phase IIb for severe fibrotic lung diseases like idiopathic pulmonary fibrosis) represent crucial near-term value inflection points. Favorable results from these trials would validate the company's therapeutic approach, enhance the attractiveness of these assets, and bring them closer to potential market approval or licensing agreements.
- Strategic Partnerships and Licensing Agreements: As a clinical-stage biotechnology company without current product sales, revenue growth for Damora Therapeutics is highly dependent on securing strategic collaborations and licensing agreements for its promising drug candidates. Successful progression through clinical milestones, particularly positive proof-of-concept data, would make the company's assets more appealing to larger pharmaceutical partners, potentially generating upfront payments and milestone-based revenues.
AI Analysis | Feedback
Share Issuance
- In February 2026, Galecto, Inc., now Damora Therapeutics, completed a public offering of common stock, raising approximately $316.3 million in gross proceeds by issuing 16,644,737 shares.
- Galecto also filed a mixed shelf registration for up to $150 million in February 2026, providing flexibility for future security issuances.
- On August 29, 2024, Galecto implemented a 1-for-25 reverse stock split of its common stock, primarily to maintain its Nasdaq listing compliance.
Inbound Investments
- In November 2025, concurrent with the acquisition of Damora Therapeutics, Galecto secured an oversubscribed private investment of approximately $285 million through a private placement of Series C non-voting convertible preferred stock.
Outbound Investments
- Galecto, Inc. completed the acquisition of privately held Damora Therapeutics, Inc. in November 2025. As part of this acquisition, Galecto issued 265,309 shares of common stock and various Series B and Series C preferred stock to Damora holders.
Capital Expenditures
- Research and development expenses for the year ended December 31, 2025, were $26.9 million, a significant increase from $6.4 million in 2024, primarily driven by preclinical study and clinical trial-related expenses, and chemistry, manufacturing, and control (CMC) activities.
- An acquired in-process research and development cost of $174.3 million was recognized in fiscal year 2025, which was associated with the asset acquisition of Damora Therapeutics.
- The company plans to use proceeds from recent offerings to fund preclinical studies, clinical trials, and manufacturing for its antibody programs, as well as general research and development activities.
Peer Outperformance in Biotechnology
DMRA has outperformed 53% of its 364 Biotechnology peers over 5Y. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that DMRA has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
99%
of 461 industry peers · 796.8% return
3Y
75%
of 406 industry peers · 92.4% return
5Y
53%
of 364 industry peers · -70.4% return
null
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is DMRA's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 4.4% | 78.3% | 158.4% | CAH 396% · MCK 329% · COR 178% |
| Health Care Services | 20 | 19.5% | 43.7% | 9.3% | HIMS 348% · RDNT 152% · DGX 75% |
| Managed Health Care | 8 | 32.5% | -5.1% | -1.2% | OSCR 132% · HQY 65% · ELV 13% |
| Health Care Facilities | 24 | 8.3% | -2.6% | -16.6% | THC 275% · NHC 266% · ENSG 123% |
| Health Care Equipment | 50 | -1.5% | -8.1% | -22.2% | POCI 10975% · UFPT 368% · GKOS 278% |
| Health Care Supplies | 12 | 37.0% | -13.7% | -25.8% | LNTH 301% · HAE 82% · MMSI 30% |
| Pharmaceuticals | 63 | 6.0% | -1.5% | -32.0% | LQDA 2643% · INDV 1326% · ETON 1259% |
| Health Care Technology | 21 | -17.7% | -55.4% | -70.5% | SPOK 117% · HSTM -3% · VEEV -22% |
| Life Sciences Tools & Services | 108 | -0.5% | -33.8% | -71.0% | SNWV 1900% · ELMD 249% · MEDP 243% |
| Biotechnology ← | 365 | 10.3% | -24.9% | -77.8% | BRTX 110200% · CELZ 1729% · DNTH 1587% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.50 |
| Mkt Cap | 1.0 |
| Rev LTM | 147 |
| Op Inc LTM | -67 |
| FCF LTM | -45 |
| FCF 3Y Avg | -83 |
| CFO LTM | -45 |
| CFO 3Y Avg | -82 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 25.7% |
| Rev Chg 3Y Avg | 18.5% |
| Rev Chg Q | 17.2% |
| QoQ Delta Rev Chg LTM | 6.4% |
| Op Inc Chg LTM | 50.1% |
| Op Inc Chg 3Y Avg | 13.9% |
| Op Mgn LTM | -36.7% |
| Op Mgn 3Y Avg | -76.7% |
| QoQ Delta Op Mgn LTM | 2.6% |
| CFO/Rev LTM | -50.2% |
| CFO/Rev 3Y Avg | -69.7% |
| FCF/Rev LTM | -50.4% |
| FCF/Rev 3Y Avg | -69.7% |
Price Behavior
Price Behavior
| Market Price | $30.31 | |
| Market Cap ($ Bil) | 1.0 | |
| First Trading Date | 10/29/2020 | |
| Distance from 52W High | -11.2% | |
| 50 Days | 200 Days | |
| DMA Price | $27.90 | $25.29 |
| DMA Trend | up | up |
| Distance from DMA | 8.7% | 19.9% |
| 3M | 1YR | |
| Volatility | 76.4% | 475.4% |
| Downside Capture | 5.54 | -78.99 |
| Upside Capture | 96.61 | 191.01 |
| Correlation (SPY) | 14.9% | 5.5% |
DMRA Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.87 | 0.87 | 0.57 | 1.11 | 2.02 | 1.87 |
| Up Beta | 1.90 | 0.73 | 0.17 | 2.07 | 7.93 | 2.01 |
| Down Beta | 2.55 | 2.79 | 1.84 | -0.87 | 2.64 | 2.66 |
| Up Capture | 262% | 75% | 51% | 173% | 323% | 322% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 9 | 17 | 28 | 55 | 114 | 339 |
| Down Capture | 83% | -27% | -0% | 133% | -121% | 111% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 12 | 25 | 34 | 69 | 132 | 394 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DMRA | |
|---|---|---|---|---|
| DMRA | 807.3% | 474.4% | 1.37 | - |
| Sector ETF (XLV) | 27.8% | 15.9% | 1.35 | 4.6% |
| Equity (SPY) | 20.3% | 12.9% | 1.16 | 5.4% |
| Gold (GLD) | 36.2% | 28.7% | 1.07 | 6.6% |
| Commodities (DBC) | 44.1% | 20.2% | 1.69 | 1.1% |
| Real Estate (VNQ) | 13.3% | 13.8% | 0.66 | -1.8% |
| Bitcoin (BTCUSD) | -38.8% | 43.2% | -1.01 | 0.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DMRA | |
|---|---|---|---|---|
| DMRA | -22.2% | 229.2% | 0.43 | - |
| Sector ETF (XLV) | 7.0% | 15.1% | 0.28 | 7.5% |
| Equity (SPY) | 12.8% | 17.2% | 0.57 | 10.5% |
| Gold (GLD) | 20.4% | 18.6% | 0.89 | 6.1% |
| Commodities (DBC) | 10.2% | 19.6% | 0.40 | 3.4% |
| Real Estate (VNQ) | 2.4% | 18.9% | 0.02 | 6.7% |
| Bitcoin (BTCUSD) | 9.3% | 52.7% | 0.36 | 6.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DMRA | |
|---|---|---|---|---|
| DMRA | -22.2% | 215.9% | 0.32 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.52 | 7.6% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 10.2% |
| Gold (GLD) | 12.4% | 16.2% | 0.63 | 6.3% |
| Commodities (DBC) | 8.1% | 18.1% | 0.37 | 3.2% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 6.5% |
| Bitcoin (BTCUSD) | 61.0% | 66.1% | 1.01 | 4.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/19/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/19/2025 | 10-K |
| 09/30/2024 | 11/01/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 04/29/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 07/31/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/10/2026 | 10-Q |
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/19/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/19/2025 | 10-K |
| 09/30/2024 | 11/01/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 04/29/2024 | 10-Q |
| 12/31/2023 | 03/08/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 07/31/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 07/29/2022 | 10-Q |
| 03/31/2022 | 04/29/2022 | 10-Q |
| 12/31/2021 | 02/17/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/04/2021 | 10-Q |
| 12/31/2020 | 03/29/2021 | 10-K |
| 09/30/2020 | 12/11/2020 | 10-Q |
| 06/30/2020 | 10/30/2020 | 424B4 |
Insider Activity
Updated 8/13/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Winslow, Garrett | General Counsel | Direct | Sell | 7072026 | 29.98 | 245 | 7,345 | 68,624 | Form |
| 2 | Schambye, Hans T | Chief Executive Officer | Direct | Sell | 1062026 | 21.38 | 700 | 14,966 | 100,101 | Form |
| 3 | Winslow, Garrett | General Counsel | Direct | Sell | 1062026 | 21.38 | 255 | 5,452 | 39,639 | Form |
| 4 | Firmani, Lori | Chief Financial Officer | Direct | Sell | 1062026 | 21.41 | 135 | 2,890 | 19,933 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Winslow, Garrett | General Counsel | Direct | Sell | 7072026 | 29.98 | 245 | 7,345 | 68,624 | Form |
| 2 | Schambye, Hans T | Chief Executive Officer | Direct | Sell | 1062026 | 21.38 | 700 | 14,966 | 100,101 | Form |
| 3 | Winslow, Garrett | General Counsel | Direct | Sell | 1062026 | 21.38 | 255 | 5,452 | 39,639 | Form |
| 4 | Firmani, Lori | Chief Financial Officer | Direct | Sell | 1062026 | 21.41 | 135 | 2,890 | 19,933 | Form |
Investor Activity (13F)
Updated Aug 21, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Remedium Capital Partners, LLC | $53.0 Mil | 18.8% | 6 | ADD +1597.9% | 13F |
| Fairmount Funds Management LLC | $225.7 Mil | 16.3% | 12 | New | 13F |
| FCPM III Services B.V. | $63.2 Mil | 8.8% | 14 | New | 13F |
| Venrock Adviser, LLC | $93.3 Mil | 3.5% | 33 | New | 13F |
| Commodore Capital LP | $50.2 Mil | 2.9% | 36 | New | 13F |
| a16z Capital Management, L.L.C. | $32.0 Mil | 2.5% | 16 | New | 13F |
| Cormorant Asset Management, LP | $39.5 Mil | 2.0% | 46 | New | 13F |
| Avoro Capital Advisors LLC | $98.0 Mil | 1.0% | 30 | New | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | $225.7 Mil | 16.3% | 12 | New | 13F |
| Avoro Capital Advisors LLC | $98.0 Mil | 1.0% | 30 | New | 13F |
| Venrock Adviser, LLC | $93.3 Mil | 3.5% | 33 | New | 13F |
| FCPM III Services B.V. | $63.2 Mil | 8.8% | 14 | New | 13F |
| Commodore Capital LP | $50.2 Mil | 2.9% | 36 | New | 13F |
| Cormorant Asset Management, LP | $39.5 Mil | 2.0% | 46 | New | 13F |
| a16z Capital Management, L.L.C. | $32.0 Mil | 2.5% | 16 | New | 13F |
| Remedium Capital Partners, LLC | $53.0 Mil | 18.8% | 6 | ADD +1597.9% | 13F |
| Active Manager |
|---|
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | $225.7 Mil | 16.3% | 12 | New | 13F |
| Avoro Capital Advisors LLC | $98.0 Mil | 1.0% | 30 | New | 13F |
| Venrock Adviser, LLC | $93.3 Mil | 3.5% | 33 | New | 13F |
| FCPM III Services B.V. | $63.2 Mil | 8.8% | 14 | New | 13F |
| Remedium Capital Partners, LLC | $53.0 Mil | 18.8% | 6 | ADD +1597.9% | 13F |
| Commodore Capital LP | $50.2 Mil | 2.9% | 36 | New | 13F |
| Cormorant Asset Management, LP | $39.5 Mil | 2.0% | 46 | New | 13F |
| a16z Capital Management, L.L.C. | $32.0 Mil | 2.5% | 16 | New | 13F |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/20/2026